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BACKGROUND. The treatment of breast cancer requires a multidisciplinary
approach, and patients are often referred to a multidisciplinary cancer clinic. The
purpose of the current study was to evaluate the impact of this approach on the
surgical management of breast cancer.
METHODS. The medical records of 149 consecutive patients referred to a multidis-
ciplinary breast cancer clinic over a 1-year period with a diagnosis of breast cancer
were reviewed retrospectively for alterations in radiologic, pathologic, surgical,
and medical interpretations and the effect that these alterations had on recom-
mendations for surgical management.
RESULTS. A review of the imaging studies resulted in changes in interpretations in
67 of the 149 patients studied (45%). This resulted in a change in surgical manage-
ment in 11% of patients. Review of the pathology resulted in changes in the inter-
pretation for 43 of the 149 patients (29%). Thirteen patients (9%) had surgical
management changes made solely as a result of pathologic reinterpretation. In 51
patients (34%), a change in surgical management was recommended after discus-
sion with the surgeons, medical oncologists, and radiation oncologists that was
not based on reinterpretation of the radiologic or pathologic findings. Overall, a
second evaluation of patients referred to a multidisciplinary tumor board led to
changes in the recommendations for surgical management in 77 of 149 of those
patients studied (52%).
CONCLUSIONS. The changes in management stemmed from differences in mam-
mographic interpretation, pathologic interpretation, and evaluation by medical
and radiation oncologists and surgical breast specialists. Multidisciplinary review
can provide patients with useful additional information when making difficult
treatment decisions. Cancer 2006;107:2346–51.  2006 American Cancer Society.
KEYWORDS: breast neoplasms, multidisciplinary, referral, consultation, breast con-
servation, mastectomy.
T he contemporary treatment of breast cancer has increased incomplexity and combined modality therapy has become the
standard of care. A multidisciplinary tumor board recognizes the
essential need for multimodality treatment in a single-center setting.
With the advent of the Internet and increased patient knowledge and
awareness, patients often seek care from a specialized cancer center.
In recent years, there has been a trend toward patient evaluation at
centers that employ a network of specialists devoted to the care of
patients with breast cancer.
The National Cancer Institute has long provided funding for
comprehensive centers with multidisciplinary treatment options.
Professional organizations such as the American Society of Breast
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Diseases and the American Society of Clinical Oncolo-
gists widely support such centers. At our institution,
patients diagnosed at outside hospitals are often
referred with the diagnosis of breast cancer for second
opinions. In some cases, complete care of the patient is
assumed, whereas in other cases the patients return to
their outside physicians. We sought to examine our ex-
perience with patients evaluated at our breast tumor
board and to determine the impact this had on the sur-
gical recommendations compared with those received
prior to review by the multidisciplinary tumor board.
MATERIALS AND METHODS
Breast Cancer Multidisciplinary Tumor Board
Patients were referred to the breast center’s multidisci-
plinary tumor board after having already been diag-
nosed with breast cancer. All patients in this study had
undergone an initial evaluation, breast imaging and
interpretation, biopsy, and recommendations for treat-
ment at outside facilities, and had presented for sec-
ond opinions. Patients are routinely instructed by our
clinical nurse specialist to have all mammograms,
ultrasound images, and pathology slides forwarded
prior to the first clinic visit, or to bring these items with
them. Referring physicians were requested to forward
all medical records and official readings prior to the
consultation.
On the morning of evaluation, each patient under-
went a thorough history and physical examination by
the surgical team. All imaging was submitted to the
breast radiologists for interpretation and the specimen
slides were submitted to the pathologists for review.
The entire team of surgeons, oncologists, radiologists,
pathologists, radiation oncologists, and nurses then
met in consultation to discuss each patient. Treatment
plans were made based on the National Comprehen-
sive Cancer Network’s (NCCN) most current clinical
guidelines for breast cancer.1 Patients often required
further diagnostics, including additional imaging stu-
dies and/or additional histologic staining. Breast mag-
netic resonance imaging was not part of the additional
imaging. These tests were completed at our center,
with the results reviewed the same day or at the next
tumor board meeting.
During the tumor board meeting, patients had
educational meetings with the clinical nurse specia-
lists, at which time they received materials and read-
ings concerning breast cancer treatment options.
They also received information from social workers
and psychologists during this session. Prior to com-
pletion of the day, the patients then met with the
involved physicians individually and the treatment
plan was discussed. They had the opportunity to ask
questions and have one-on-one consultations with all
involved physicians. Follow-up appointments and/or
bookings for surgery, chemotherapy, or radiation
planning were made at the time of the initial visit for
those patients who opted to transfer their care. Full
details of the tumor board recommendations were
communicated back to the outside physicians for
those patients who came for a second opinion only.
The records of 149 consecutive patients referred to
the multidisciplinary tumor board for a second opi-
nion over a 1-year time period between July 2000 and
June 2001 were reviewed retrospectively. Patients with-
out an outside treatment recommendation were ex-
cluded from the study, as were patients initially
diagnosed at the University of Michigan. With the ap-
proval of the Institutional Review Board, the records
for these patients were retrospectively reviewed for
alterations in radiologic, pathologic, surgical, and medi-
cal interpretations and the effects that these alterations
had on recommendations for surgical management and
clinical treatment were examined.
RESULTS
Review of Outside Imaging
Review of the outside imaging by dedicated breast
radiologists resulted in changes in previous interpreta-
tions in 67 of the 149 patients studied (45%). The most
common change was the identification of additional
lesions. Overall, 43 patients (29%) were recommended
to undergo an additional biopsy or an alteration in
follow-up imaging. Six patients had residual findings at
the site of a previous excision (4%), and 18 patients
(12%) had a change in the level of suspicion in a pre-
viously noted lesion (Table 1).
Based on review of imaging and additional studies
obtained at our institution, a change in the follow-up
was suggested for 10 patients (7%). Twenty-four pa-
tients underwent biopsies of second lesions or excision
of residual lesions. Of the patients undergoing these
additional procedures, 12 (50%) had benign findings, 8
(33%) demonstrated additional or residual cancer, and
4 patients (17%) underwent their biopsy at another
center for which the results are unknown. In all, 16 of
149 patients (11%) had a change in surgical manage-
ment made based on rereview of the breast imaging:
TABLE 1
Radiologic Interpretation Changes after Review (n 5 149)
Change in management No. %
Additional lesions 43 28.9
Residual abnormality after surgery 6 4.0
Increased or decreased suspicion of lesion 18 12.1
Total 67 45.0
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8 patients as a result of the additional biopsies and
8 patients based on radiographic review alone (Table 2).
Review of Outside Pathology
Review of the histologic slides by dedicated breast
pathologists resulted in changes in the interpretation
for 43 of 149 patients (29%). Six patients (4%) originally
diagnosed with ductal carcinoma in situ (DCIS) had
their diagnoses changed to lobular carcinoma in situ
and/or atypical ductal hyperplasia. One patient was
upgraded from benign disease to cancer and 2 patients
had their diagnoses changed from DCIS to invasive
disease. Twenty-six patients (17%) had changes in tu-
mor grade or subtype, and 8 patients (5%) had changes
to the surgical margin status as a result of consultation
with pathologists during the multidisciplinary tumor
board (Table 3). This resulted in a change in surgical
management for 13 patients (9%), solely as a result of
pathologic reinterpretation (Table 4).
Clinical Review by the Multidisciplinary Tumor Board
Case review at the tumor board led to changes in the
recommended surgical management that were not
based on the interpretation of the radiologic or patho-
logic findings in 48 patients (32%), but rather based
on NCCN guidelines as interpreted by the surgeons,
radiation oncologists, and medical oncologists only
(Table 5). In some cases, this represented a difference
in the management approach. Five patients were re-
commended by outside surgeons for mastectomy but
had no contraindications to breast conservation. Two
patients were recommended for breast conservation
but were not candidates for adjuvant radiation. The
multidisciplinary tumor board recommended that 19
patients undergo a sentinel lymph node (SLN) biopsy.
In the majority of these patients, this was because the
outside surgeon recommended axillary lymph node
dissection (ALND) for staging. In some cases, surgical
changes were made based on findings at physical ex-
amination, specifically the identification of clinically
palpable axillary lymph nodes for which ALND was
recommended after confirmation by fine-needle as-
piration.
In some cases, the changes were made based on our
approach to breast cancer treatment. Eleven patients
initially were recommended to undergo a mastectomy;
however, after review at the tumor board, our
TABLE 2
Changes in Surgical Management Based on Review of Breast
Imaging (n 5 149)
Change in management No. %
Second cancer detected after biopsy of additional lesion,
precluding BCT 8 5.4
Reexcision lumpectomy for residual calcifications noted
on postlumpectomy mammogram 3 2.0
Mammographic findings precluding recommended BCT 2 1.3
Neoadjuvant chemotherapy recommended instead of mastectomy 2 1.3
ALND recommended 1 0.7
Total 16 10.7
BCT indicates breast-conserving therapy; ALND, axillary lymph node dissection.
TABLE 3
Pathologic Interpretation Changes after Consultation (n 5 149)
Change No. %
Downgrade to benign disease 6 4.0
Upgrade from benign disease to cancer 2 1.3
Upgrade from DCIS to invasive cancer 1 0.7
Change in tumor grade or subtype 26 17.4
Change in surgical margin status 8 5.4
Total 43 28.8
DCIS indicates ductal carcinoma in situ.
TABLE 4
Changes in Management Based on Review of the Pathology
Change in management No. %
No further surgery needed (cancerous lesion actually benign) 2 1.3
Axillary LN evaluation not recommended
(invasive cancer actually in situ) 1 0.7
Axillary LN evaluation recommended
(in situ cancer actually invasive) 1 0.7
Reexcision lumpectomy recommended
(negative surgical margins actually positive) 5 3.3
Adjuvant chemotherapy recommended
(change in tumor grade) 4 2.7
Total 13 8.7
LN indicates lymph node.
TABLE 5
Changes in Recommended Surgical Management after
Tumor Board Review
Change in management No. %
Candidate for breast conservation recommended
for mastectomy 5 3.4
Recommended for breast conservation but not an
appropriate candidate 2 1.3
Sentinel LN biopsy recommended rather than ALND or
no axillary LN evaluation 19 12.8
ALND recommended for positive sentinel LN or clinical
evidence of axillary LN disease 8 5.4
Reexcision lumpectomy recommended for close surgical margins 3 2.0
Neoadjuvant treatment recommended rather than mastectomy 11 7.4
LN indicates lymph node; ALND, axillary lymph node dissection.
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recommendation was for neoadjuvant chemotherapy
with a possible attempt at breast conservation therapy.
Three patients were recommended to undergo a reex-
cision lumpectomy based on our management of sur-
gical margins measuring <2 mm.
When the changes in recommendations based on
the radiologic, pathologic, and clinical reviews were
combined, a total of 77 of the 149 patients evaluated
(52%) had 1 changes in recommendations for surgi-
cal treatment. This group included 11 patients who
had changes in 1 area of evaluation.
DISCUSSION
In 1985, the University of Michigan Medical Center
established a multidisciplinary breast care center to
provide comprehensive diagnosis and treatment for
women with both benign and malignant disease.2 The
National Breast Cancer Coalition has defined a compre-
hensive multidisciplinary program as one that includes
general breast and reconstructive surgery, hormonal
therapy, chemotherapy, imaging, radiation oncology,
clinical trials, and complementary and alternative thera-
pies, as well as physical, mental, and emotional support.
Administrative duties such as scheduling, billing, and
record keeping are also integral parts of an established
program. Other advantages such as high-risk genetics
counseling and assessment, lymphedema services, and
transportation programs have proved invaluable in the
complete care of breast cancer patients.
Although many centers have long utilized tumor
boards for other cancers, there are several clear fac-
tors supporting the treatment of breast cancer by a
multidisciplinary tumor board. The most obvious
advantage is the opportunity to review the results of
radiology and pathology. There is known variability in
radiologists’ interpretation of mammograms,3 and
specialists in breast imaging tend to detect more
abnormalities compared with general radiologists.4 It
is suspected that these results are likely due both to
training and continuing specialty education in mam-
mography, and the volume of mammographic inter-
pretation. Expert breast pathology assessment is also
becoming essential in breast cancer. Our results coin-
cide with other national reports in which specialist
review led to the reclassification of pathologic find-
ings. Staradub et al.5 examined how often the patho-
logic second opinion resulted in changes in the
surgical management and diagnosis. They found that
specialty pathology review provided additional prog-
nostic information in 40% of those cases studied and
that major changes in pathology led to altered surgi-
cal therapy in 7.8% of patients. This is likely due in
part to the consistent standards and boundaries set
by breast specialty groups of pathologists with regard
to grading and types of cancers. The findings of both
the current study and others suggest that expert radi-
ology and pathology assessment is necessary in the
routine treatment of breast cancer.4,6,7
Another significant advantage at the forefront of
the multidisciplinary breast cancer tumor board is the
ability to disseminate new research findings and treat-
ment strategies. This includes not only new systemic
therapies and regimens, but also surgical manage-
ment. SLN biopsy for surgical staging, downstaging
tumors for breast conservation by means of neoad-
juvant chemotherapy, and immediate reconstruction
after skin-sparing mastectomy are relatively newer sur-
gical concepts. Even breast conservation therapy, the
safety of which was demonstrated in randomized trials
more than 25 years ago,8–14 is still not applied uni-
formly.15 The incorporation of new treatment modal-
ities requires the input of not just the surgeon but also
the radiation oncologist (who must feel comfortable
delivering radiation after lumpectomy or may recom-
mend radiation after mastectomy) and the medical
oncologist (for whom the staging information may
change the management of the patient or who must
assess the patient’s suitability for systemic therapy).
The basis for these medical decisions must reflect out-
comes and clinical trials data and requires broad input
across several disciplines.
In the current study, several patients who were can-
didates for breast conservation initially had been re-
commended to undergo mastectomy. Nationally, breast
conservation is often underutilized. Examining the Sur-
veillance, Epidemiology, and End Results (SEER) registry
data from the National Cancer Institute, Lazovich et al.
studied the frequency of breast-conserving therapy in
different areas of the U.S. over the course of 11 years
(1985–1995).16 They found that increasing age, Stage II
disease, decreasing median income, decreasing educa-
tional level, and residence outside the region’s major
medical center all were factors predictive of an increased
probability of treatment with mastectomy.
Although many patients may not require mastec-
tomy, the key to successful breast conservation is the
appropriate selection of patients. Patients with multi-
centric disease or diffuse microcalcifications are poor
candidates, and the current data revealed several inci-
dences in which biopsy of additional lesions demon-
strated multicentricity or review of the mammography
demonstrated diffuse microcalcifications that precluded
breast-conserving therapy. Reexcision for positive surgi-
cal margins or residual calcifications was recommended
in 8 patients. Postlumpectomy mammograms to detect
residual clinical disease in patients who had microcalci-
fications will do so in a significant number of patients
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and their routine use is recommended, even when neg-
ative surgical margins are obtained.17,18 In some pa-
tients, we recommended reexcision for close (<2 mm)
margins. This may represent a more aggressive ap-
proach at our institution; other surgeons may perceive
close but negative surgical margins as margins that do
not require reexcision. To our knowledge, the defini-
tion of ‘‘close’’ surgical margins varies among institu-
tions, and the effect of reexcision on local recurrence
remains unknown; however, several reviews have de-
monstrated a higher local recurrence rate with close
surgical margins.19–21
SLN biopsy has become increasingly accepted in
the staging of the axilla for breast cancer and is now
routinely performed in most large medical centers.
The NCCN currently considers patients newly diag-
nosed with invasive breast cancer who are without
prior chemotherapy or hormonal therapy to be candi-
dates for SLN biopsy for surgical axillary lymph node
staging. Although many large prospective trials have
confirmed its accuracy and safety, to our knowledge
SLN biopsy has not yet been widely accepted in many
community-based and rural settings. For example, in
a survey of rural surgeons in Kentucky, 87% per-
formed breast cancer surgery yet only 54% performed
SLN biopsy.22 In the current study, 27 patients (18%)
had changes in their axillary lymph node management
recommended. Many of these cases, noted among
patients evaluated between 2000 and 2001, centered
on the use of SLN biopsy in clinically lymph node-neg-
ative patients. As the results of randomized studies are
published and more surgeons are trained in the tech-
nique of SLN biopsy, this should become a less fre-
quent occurrence.
Over the past decade, neoadjuvant chemotherapy
has also become more common. It has been shown
that preoperative chemotherapy substantially reduces
the size of the primary tumor and lymph node metas-
tases in up to 80% of patients, often rendering these
patients candidates for breast conservation therapy.23
Several multiinstitutional randomized trials have
demonstrated an increase in breast conservation rates
after neoadjuvant chemotherapy.24–28 Thirteen patients
(9%) in the current study had their management chan-
ged to include neoadjuvant chemotherapy based on
surgical opinion and input from radiology and medical
oncology specialists.
As with all retrospective reviews, the current study
has limitations. The final recommendations from the
tumor board were based on the best judgment of the
involved physicians for each patient. Although the
overall goal of the multidisciplinary team is to follow
standard NCCN guidelines, physician preference and
opinions may influence decisions. Although there are
departmental controls in place to assist in accuracy,
there were no internal controls to determine whether
the final radiology, pathology, or surgical decisions
were, in fact, the correct conclusions for each case. Tu-
mor board evaluation with cautious readings resulted
in additional images and biopsies, and not all of these
were malignant. However, based on the latest research
findings, the effect on patient outcomes and survival is
also unknown. Until outcome data are examined, the
true risk-versus-benefit ratio is unknown. This is parti-
cularly significant when one considers the cost-effec-
tiveness of this approach, which was not evaluated in
the current study and may be prohibitive in some hos-
pital settings.
Conclusions
The data from the current study revealed that greater
than half (77 of 149 patients) of the patients evaluated
at a breast cancer tumor board over the course of 1 year
had changes in their recommended surgical treatment
made based on radiographic, pathologic, and/or clini-
cal interpretation. At least 7% of patients had previously
undetected or residual cancers. There is emerging liter-
ature that supports breast cancer treatment involving
the collaborative efforts of multiple medical specialties.
The results of the current study demonstrate that the
multimodality approach can provide important addi-
tional information, allowing expert opinion and re-
commendations based on the most recent research
findings in 1 setting, resulting in changes in patient
management.
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